enoticumab (REGN421) / Regeneron - LARVOL DELTA

Delta-like Ligand 4 Inhibitors Induce Pulmonary Arterial Hypertension in Clinical Trials (AHA 2024) - "The most common antibody used was Demcizumab(6), followed by Navicixizumab(2), Dilpacimab(2), ABL001(2), and Enoticumab(1). DLL-4 inhibition treatment for malignancies has demonstrated PAH as a side effect. These results are in accordance with our previous observation that unopposed JAG-1-NOTCH3 signaling, induces pulmonary vascular SMC proliferation and PAH. Discontinuation of DLL-4 inhibitors leads to resolution of disease."

Clinical • Cardiovascular • Oncology • Pulmonary Arterial Hypertension • Respiratory Diseases • NOTCH3

[VIRTUAL] Interruption of Notch Signaling via Blockade of Delta-Like Ligand 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection (ATC 2021) - "These data demonstrate that anti-DLL4 blockade is a promising therapy to suppress co-stimulation resistant alloreactivity and may help facilitate clinical translation of anti-DLL4 therapies in conjunction with Belatacept."

Nephrology • Transplantation • CD40LG • CD8 • IFNG • TNFA

A multiple-ascending-dose study of the safety and tolerability of REGN421(SAR153192) in patients with advanced solid malignancies (clinicaltrials.gov) - P1, N=83; Sponsor: Regeneron; Active, not recruiting -> Completed.

Trial completion • Oncology

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1; N=83; Completed; Sponsor: Regeneron Pharmaceuticals; Active, not recruiting -> Completed

Trial completion • Biosimilar • Oncology

Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors (ASCO 2013) - Presentation time: Sunday, Jun 2, 8:00 AM - 11:00 AM; Abstract #2502; P1, N=53; NCT00871559; Sponsor: Regeneron; "REGN421 had an acceptable safety profile, and RP2Ds of 4mg/kg Q3W and 3mg/kg Q2W. Responses and prolonged SD were noted in OvCa pts and other solid tumors"

P1 data • Oncology